MECOMATION DISCLOSURE	Application Number		10571311		
	Filing Date		2006-03-09		
	First Named Inventor	WUR	ST		
	Art Unit		1617		
	Examiner Name	SOROUSH			
	Attorney Docket Numb	or	2723411		

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Patentee or Applicant Releva			s,Columns,Lines where ant Passages or Relevant es Appear		
	1										
If you wisl	If you wish to add additional U.S. Patent citation information please click the Add button. Add									_	
			U.S.P	ATENT.	APPLK	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite I	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Releva		es,Columns,Lines where evant Passages or Relevant eres Appear			
	1								Add		
If you wisi	n to ac	d additional U.S. Publ		,		ENT DOCUM		d button	Remove	1	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code4	Publication	Name of Patentee or Applicant of cited		Pages,Columns,Lines		TE
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								_			
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Initials* Cite Initials* No (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10571311	
iling Date		2006-03-09	
irst Named Inventor	WURST		
Art Unit		1617	
Examiner Name	SOROUSH		
Attorney Docket Number		27234U	

	1	BIERREFI, C., et al., "Efficesy and salety of observative companed with buddenside in astima patients: a randomized 12 weet shulfy." Presented as a poster at the SSIs International Conference of the American Thoraco Society (ATS), May 16-21, 2005, Seatile, Wales, Am J Roepe Cot Care Med., 2005, 167. Adeltand A1499.					
	2	BOULET, IP., et al., "Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma". Presented as a poster at the 95th international Conference of the American Thoraco Society (ATS), May 10-21, 2003, Serial, Westl., Am 3 Paper Crit Care Med., 2003, 167, Alexander AT-508.					
	3	BUNDSCHUH, D.S., et al., "[1013] Pre-clinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciciesonide", Oral Presentation: New developments in inhaled conticosteroid therapy (2.45 PM - 4.45 PM) Sunday, September 23, 2001, 2.45 PM, Hall 4/5.					
	4	DEROM, E., et al., "Efficacy and systemic effects of ciclesonide and fluticesone in asthma patients", Oral presentation at the 11th Annual Congress of the European Respiratory Society (ERS); September 22-26, 2001; Berlin, Germany, Eur Respir J, 2001; 18: Abstract 1015.					
	5	ENGELSTATTER, R., et al., "Comparative study in astirms patients treated with inhaled ciclesonide (80 µg or 320 µg once daily) or budesonide (200 µg lowise daily) for 12 weeks", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003, Seattle, Wash., Am J Respir Crit Care Med., 2003, 167: Abstract A1511.					
	6	HANSEL, T., et al., "Once daily ciclesonide (80 µg or 300 µg) is equally effective as budesonide 200 µg given twice daily a 12-week shoty in asterna patients". Eur Resper J 2003; 22 Suppl 43 4.10 Hap poster presented at the 13th Annual Congress of the European Respeatedry Scolery, 6003, September 27-Ostober 1; Vennar, Abertart nr. P2639.					
	7	KANNIESS, F., et al., "Effect of Inhaled Ciclesonide on Airway Responsiveness to Inhaled AMP, the Composition of Induced Sputum and Exhaled Nitro Oxide in Patients with Mild Asthma", Pulmonary Pharmacology & Therapeutics, (2001), 14, 141-147, © 2001 Academic Press.					
	8	SZEFLER, S.J., Deputy Editor, "Early intervention for childhood astitum: Inhaled gluccoortooids as the "preferred" medication", J Allergy Clin Immunol 1996, 102: 719-721, © 1996 by Mostly, Inc.					
	9	UKENA, D., et al., "Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study", Eur Respir J 2003; 22 (Suppl. 45): 411s, Plus poster presented at the 13th Annual Congress of the European Respiratory Society, 2000; September 27-October 1; Vienna, Abstract no P2640					
	10	WAGENER, J.S., et al., "Inhaled steroids in children: Risks versus rewards", The Journal of Pediatrics, Volume 132, Number 3, Part 1, Pages 381-383, 0 1988 by Mosby, Inc.					
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add						

	Application Number		10571311		
	Filing Date		2006-03-09		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	WUR	ST		
	Art Unit		1617		
	Examiner Name	SOR	DUSH		
	Attorney Docket Numb	er	27234U		

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

16e Kin Codes of USPTO Patert Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the hoveletic rode (WIPO Standard S13.) 3 "For implance patent for comments, the included on the year of the import norm precede the serial rode plasted document, and occurrently the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. 9 Applicant is to place a check mark here if English languages translation to statistics.